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E-mail address: mc@life.ku.dk (M. Christensen).Major acute phase proteins (APPs) have proven diagnostically useful in dogs, cats and horses with routine
use facilitated by commercially available automated heterologous assays. An automated assay applicable
across all three species would highly facilitate further dissemination of routine use, and the aim of this
study was to validate an automated latex agglutination turbidimetric immunoassay based on monoclonal
anti-human serum amyloid A (SAA) antibodies for measurement of canine, feline and equine SAA. Serum
samples from 60 dogs, 40 cats and 40 horses were included. Intra- and inter-assay imprecision, linearity
and detection limit (DL) were determined to assess analytical performance. To assess clinical perfor-
mance, equine and feline SAA measurements were compared with parallel measurements using a previ-
ously validated automated SAA assay in a method comparison setting, and by assessing overlap
performance of canine SAA in healthy dogs and diseased dogs with and without systemic inﬂammation.
Intra- and inter-assay CVs ranged between 1.9–4.6% and between 3.0–14.5%, respectively. Acceptable
linearity within a clinically relevant range of SAA concentrations was observed for all three species. The
DL was 1.06 mg/L. Method comparison revealed acceptable agreement of the two assays measuring feline
and equine SAA, and the overlap performance of canine SAA was acceptable. The tested assay measured
SAA in canine, feline and equine serum with analytical and overlap performance acceptable for clinical
purposes so improving practical aspects of clinical APP application. The monoclonal nature of the anti-
bodies suggests strong, long-term inter-batch performance stability.
 2012 Elsevier Ltd. All rights reserved.Introduction
Major acute phase proteins (APPs) have proven to be diagnosti-
cally useful as routine inﬂammatory markers in major companion
animal species including dogs, cats, and horses (Sasaki et al., 2003;
Jacobsen and Andersen, 2007; Nakamura et al., 2008). Automated
human turbidimetric immunoassays (TIA) have previously been
validated for measurements of feline and equine serum amyloid
A (SAA) (Hansen et al., 2006; Jacobsen et al., 2006a) and canine
C-reactive protein (CRP) (Kjelgaard-Hansen et al., 2003; Kjelg-
aard-Hansen, 2010; Klenner et al., 2010), facilitating dissemination
of the routine applicability of APPs (Kjelgaard-Hansen and Jacob-
sen, 2011). However, even though their diagnostic potential has
been known for decades, routine measurement of APPs is still
not as widely applied as expected (Eckersall, 2004).ll rights reserved.
rence of the European Society
2011.Development of an automated assay applicable for measure-
ments of major APPs across all three species (canine, feline and
equine) would markedly improve the practical aspects and dissem-
ination of measuring major APPs for routine diagnostic purposes.
SAA is an obvious target for a multi-species assay as it is a major
APP in all species of interest in veterinary medicine (Kjelgaard-
Hansen and Jacobsen, 2011). Moreover, the diagnostic potential
of SAA measurement in feline and equine medicine is well estab-
lished (Sasaki et al., 2003; Jacobsen and Andersen, 2007) and sev-
eral studies have shown that canine SAA also can be diagnostically
useful as a routine inﬂammatory marker most likely comparable to
the diagnostic capacity of other canine APPs (Chikamune et al.,
1998; Dabrowski et al., 2007, 2009). For diagnostic laboratories
investing in APP assays, the presence of a single assay for several
animal species would be an obvious advantage (Kjelgaard-Hansen
and Jacobsen, 2011). Furthermore, if the assay was based on mono-
clonal antibodies, stable long-term and inter-batch performance
would be possible (Kjelgaard-Hansen, 2010).
The aim of the present study was to evaluate the analytical per-
formance of an automated latex agglutination turbidimetric
immunoassay (LAT) based on monoclonal anti-human SAA
Table 1
Intra- and inter-assay coefﬁcients of variation (CV) for canine, feline, and equine
serum amyloid A (SAA) measured by a latex agglutination immunoassay based on
monoclonal anti-human SAA antibodies. SD, standard deviation.
Canine SAA Feline SAA Equine SAA
Intra-assay CV Intermediate concentration
Range (mg/L) [67.7;75] [39.9;46.2] [42.8;45.2]
Mean (mg/L) 72.6 44.1 43.5
SD 3.0 2.0 0.9
CV (%) 4.1 4.6 2.1
Intra-assay CV High concentration
Range (mg/L) [909.2;973.6] [170.5;188.9] [1491;1668]
Mean (mg/L) 931.6 177.6 1612
SD 17.5 7.1 52.1
CV (%) 1.9 4.0 3.2
Inter-assay CV Intermediate concentration
Range (mg/L) [55.2;77.5] [39.4;46.1] [34.3;46.1]
Mean (mg/L) 68.6 42.7 41.3
SD 8.6 2.9 4.8
CV (%) 12.5% 6.7% 11.6
Inter-assay CV High concentration
Range (mg/L) [687.5;946.0] [130.5;188.9] [1491;1668]
Mean (mg/L) 801.5 160.8 1543
SD 77.6 23.3 46.0
CV (%) 9.7 14.5 3.0
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included an assessment of imprecision, inaccuracy and detection
limit (DL), as well as a comparison with an established method
for diagnostic measurements of feline and equine SAA and an eval-
uation of the overlap performance of canine SAA.
Materials and methods
Assay
An LAT based on monoclonal anti-human SAA antibodies was evaluated in the
study. The assay was developed in collaboration with EIKEN Chemical Company for
measurements of canine, feline, and equine SAA. Data demonstrating the speciﬁcity
of the monoclonal antibodies in the detection of SAA are provided in Appendix A
(Supplementary material). The measurements with the LAT and the commercial
available human SAA TIA (Hansen et al., 2006; Jacobsen et al., 2006a) were per-
formed using an automated clinical chemistry analyser (ADVIA 1800, Siemens).
The LAT was calibrated using heterologous calibration material, meaning that the
concentrations measured in mg/L were in human equivalents of SAA, rather than
exact concentrations of species-speciﬁc SAA.
Samples
Serum samples from 60 dogs, 40 cats and 40 horses obtained for diagnostic pur-
poses were included in the study. All samples were taken from client-owned ani-
mals. The study was approved by the local ethical committee. All animals
underwent clinical examination during the period January 2010 to May 2011, and
blood samples were analysed at the Central Laboratory, Department of Small Ani-
mal Clinical Sciences, University of Copenhagen, Denmark. Remaining serum was
stored in plastic vials at 20 C until analysis. Samples were only thawed when
needed for analysis in order to limit freeze–thaw cycles.
Assay characteristics
The intra- and inter-assay variations were determined as the coefﬁcient of var-
iation (CV) based on replicate measurements of SAA in serum pools within the same
analytical run (same day) (n = 8–16) and across analytical runs (different days)
(n = 6–8), respectively. Pools containing intermediate concentrations of SAA (40–
45 mg/L for horse and cat and 70–75 mg/L for dogs, respectively) and pools with
high concentrations of SAA (>900 mg/L for canine SAA, >170 mg/L for feline SAA,
and >1500 mg/L for equine SAA) were used. The DL was calculated from replicate
determinations of blanks (distilled water) (n = 8).
Inaccuracy was investigated by linearity under dilution. Pooled samples with
very high concentrations of canine and feline SAA were initially diluted 0%, 10%,
20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% and 100% using distilled water; subse-
quently, in order to get a more detailed picture of the inaccuracy at high and low
concentrations, additional dilutions were made (5%, 15% and 95%). Because extre-
mely high concentrations of SAA are occasionally observed in equine serum (Jacob-
sen et al., 2006b), an even more detailed spectrum of dilutions of such an extreme
sample were made for this particular species, namely, 0%, 1%, 2%, 3%, 4%, 5%, 6%, 7%,
8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%,
85%, 90%, 95% and 100%. This was done to test for possible pro-zone effect having
a clinical impact. Expected concentrations of SAA for each dilution were calculated
from the observed concentrations in undiluted canine and feline serum and in 25%
dilution of the equine serum, respectively, and the linearity was investigated visu-
ally and by linear regression.
A method comparison for measurements of feline and equine SAA was per-
formed comparing results obtained by the LAT to measurements of SAA using a
commercial available TIA validated for SAA measurements in cats and horses (Han-
sen et al., 2006; Jacobsen et al., 2006a). Parallel measurements of SAA in 40 individ-
ual equine serum samples and 40 individual feline serum samples were used for the
method comparisons (Jensen and Kjelgaard-Hansen, 2006). The serum samples
were chosen in order to cover the full spectrum of SAA concentrations most fre-
quently expected in clinical settings. The LAT was considered reliable for diagnostic
measurements of feline and equine SAA if the performance could be shown to be
comparable to the reference method already used for routine diagnostic measure-
ments of SAA (Jacobsen and Andersen, 2007).
Overlap performance
SAA is a major positive APP in dogs (Cerón et al., 2005). If the LAT should be con-
sidered reliable for diagnostic assessment of the acute phase response, the overlap
performance of SAA measured by the LAT should be acceptable and able to discrim-
inate dogs with inﬂammatory disease from healthy dogs and dogs without inﬂam-
matory disease (Kjelgaard-Hansen et al., 2003; Nakamura et al., 2008; Yuki et al.,
2010; Hagman, 2011). Based on the ﬁnal clinical diagnoses, 60 dogs were retrospec-
tively assigned to three groups: (1) clinically healthy dogs (n = 20); (2) dogs with
systemic inﬂammation (n = 20), and (3) diseased dogs without systemic inﬂamma-tion (n = 20). For all dogs basic hematologic and clinical chemical proﬁles were ana-
lysed (Jensen et al., 2001). Additional diagnostic tests for each dog were conducted
at the discretion of the individual clinician (e.g. radiography, ultrasonography, MRI,
CSF, endocrine testing, cytology or histopathology).
Clinically healthy dogs had unremarkable ﬁndings on physical and clinical path-
ological examinations (n = 20). Diseased dogs without systemic inﬂammation were
diagnosed with idiopathic epilepsy (n = 7), syringomyelia (n = 2), cardiac disorders
(myxomatous mitral valve disease or dilated cardiomyopathy) (n = 3), arthrosis
(n = 2) or other disorders without any signs of systemic inﬂammation (n = 6). Dogs
classiﬁed with systemic inﬂammation were hospitalized because of trauma (n = 4),
pyometra (n = 2), severe meningitis (n = 3), acute gastroenteritis (n = 4), acute
symptoms of chronic gastrointestinal disorders (n = 2) or other disorders with a sys-
temic inﬂammatory response (n = 5).
A comparable spectrum of ages, sexes, and breeds were included in each group.
Statistics
Intra- and inter-assay CVs were calculated using routine descriptive statistical
procedures (Büttner et al., 1980). Imprecision performance was deemed acceptable
if comparable to previously validated automated assays measuring major APPs,
which have demonstrated sufﬁcient analytical performance for clinical applicability
(Kjelgaard-Hansen et al., 2003; Hansen et al., 2006; Jacobsen et al., 2006a). Investi-
gation of linearity under dilution was accomplished by Deeming regression analy-
sis. Linearity performance was deemed acceptable if slope and Y-intercept did not
deviate from 1 and 0, respectively.
The method comparison was performed by Deeming regression, and the Pear-
son’s correlation coefﬁcients were calculated. Agreement between methods was as-
sessed by deviations from line of agreement (Y = X). Pearson’s correlation
coefﬁcients close to 1 indicated positive correlation.
Runs test was performed in all types of regression analyses to determine
whether data deviated signiﬁcantly from the applied linear model. Overlap perfor-
mance was assessed by comparison of SAA concentrations among groups of dogs
using Dunn’s multiple comparison test and visual assessment of scatter plots. Sig-
niﬁcant discrimination between the group of dogs with systemic inﬂammation




Intra- and inter-assay CVs ranged from 1.9% to 4.6% and from
3.0% to 14.5%, respectively, in measurements of high and interme-
diate concentrations of SAA (Table 1). When investigating linearity
under dilution, a deviation from linearity was observed in the mea-
surements of high concentrations of SAA limiting the working
range of the assay for all three species (Fig. 1A–C). Introduction
Fig. 1. Linearity under dilution of canine (A and D), feline (B and E), and equine (C and F) serum containing high concentrations of serum amyloid A (SAA). The limited
working range observed without reﬂex dilution of samples with high concentrations (A–C) was widened to be clinically relevant implying a 1:6 reﬂex dilution (canine when
>300 mg/L; equine when >300 mg/L, and feline when >100 mg/L) (D–F). The dashed lines illustrate lines of agreement (Y = X).
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centrations >300 mg/L and feline samples with SAA concentrations
>100 mg/L expanded the range of acceptable linearity to a clini-
cally relevant range for all species investigated (Fig. 1D–F). After
reﬂex dilution, acceptable linearity was observed in the following
working range: 0–1000 mg/L for canine SAA, 0–700 mg/L for feline
SAA and 0–2500 mg/L for equine SAA (Fig. 1D–F) with observedTable 2
Linearity under dilution of canine, feline and equine serum pools with high serum
amyloid A (SAA) concentrations after reﬂex dilution of canine and equine samples
with SAA concentrations exceeding 300 mg/L and feline samples containing SAA
concentrations above 100 mg/L. CI, conﬁdence interval; P (runs test), probability for
ﬁtting a linear model.
Canine SAA Feline SAA Equine SAA (<2500 mg/L)
Y-intercept 4.03 15.0 47.7
[95% CI] [22.95;31.0] [1.3;31.3] [104;8.9]
Slope 1.0 1.03 1.034
[95% CI] [0.95;1.05] [0.98;1.07] [0.98;1.09]
P (Runs test) 0.51 0.025 0.226
r 0.994 0.997 0.996slopes and Y-intercept not deviating from 1 and 0, respectively (Ta-
ble 2). Speciﬁcally for equine samples the quantitative ability
ceased above 2500 mg/L, however, importantly no clinically rele-
vant prozone effect for concentrations up to 10000 mg/L were ob-
served, meaning that no tendencies of false low results were seen,
even with signiﬁcant excess of antigen in the antigen–antibody
reactions of the assay. DL was estimated to be 1.06 mg/L.Method comparison
A high degree of correlation was observed between SAA con-
centrations measured by LAT and measurements using the previ-
ously validated commercially available TIA (Table 3). Method
comparison revealed a proportional disagreement for measure-
ments of both feline and equine SAA (slope differing from 1)
and an additional systematic inaccuracy for equine SAA (Y-inter-
cept differing from 0) (Table 3). The proportional disagreement
was conﬁrmed by direct plot of SAA measurements obtained by
the two assays (Fig. 2A and B), visualising the tendency of the
LAT to measure higher concentrations of SAA than the previously
validated TIA.
Table 3
Deeming regression of the method comparison between equine and feline serum
amyloid A (SAA) measured by the novel latex agglutination turbidimetric immuno-
assay and a previously validated commercial available method.
Feline SAA Equine SAA
Slope 4.7 1.34
[95% CI] [4.11;5.32] [1.17;1.5]
Y-intercept 24.5 275
[95% CI] [56.0;7.07] [98.7;452]
r 0.87 0.87
Fig. 2. Comparison of feline (A) and equine (B) serum amyloid A (SAA) concentra-
tions measured by the novel latex agglutination turbidimetric immunoassay (LAT)
and a previously validated commercial turbidimetric immunoassay (TIA). The
dashed line illustrates line of agreement (Y = X).
Fig. 3. Serum amyloid A (SAA) concentrations in serum from healthy and diseased
dogs illustrating the overlap performance of SAA in the distinction of disorders with
and without inﬂammation. Horizontal lines, mean concentrations.
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As illustrated in Fig. 3, higher concentrations of SAA were ob-
served in dogs with systemic inﬂammation compared to healthy
dogs or diseased dogs without systemic inﬂammation, as expected
for a major APP. High concentrations of SAA were observed in pa-
tients with systemic inﬂammation, and low concentrations were
measured in patients without inﬂammation (Fig. 3). The multiple
comparison test showed that this difference was signiﬁcant
(P < 0.05).
Discussion
In the present study the novel LAT based on monoclonal anti-
human SAA antibodies was evaluated for measurements of SAA
in dogs, cats, and horses. The reliability of the assay was found to
be acceptable for determination of SAA in canine, feline, and
equine serum with comparable inter- and intra-assay imprecision
across the species. The observed inter- and intra-assay CVs
were comparable with commercially available methods for mea-
surement of feline and equine SAA and canine CRP, respectively(Kjelgaard-Hansen et al., 2003; Hansen et al., 2006; Jacobsen
et al., 2006a). Acceptable linearity was observed within a clinically
relevant working range.
Speciﬁcally for equine SAA, where extremely high SAA values
are occasionally observed in clinical disease (Jacobsen et al.,
2006b), no prozone effect was observed in concentrations up to
10,000 mg/L. The assessed absolute concentration of 10,000 mg/L
may be due to the heterologous calibration of the assay rather than
the SAA concentrations actually being so high. However, the key
ﬁnding is the lack of a prozone effect, meaning that no false low
concentrations were measured, even when the LAT antibodies
were completely saturated with SAA. A plateau was reached when
concentrations exceeded 2500 mg/L, and precise monitoring in pa-
tients with SAA concentrations persistently exceeding this limit
will therefore need further dilution, either manually or as a second
reﬂex dilution step. Because of the short half-life of SAA, the con-
centration is, however, expected to decrease quickly in diseased
horses subdued to effective treatment (Jacobsen and Andersen,
2007). Horses with SAA concentrations persistently >2500 mg/L
are therefore likely to have a persistent acute phase reaction, mak-
ing SAA concentrations persistently >2500 mg/L clinically useful.
Acceptable linearity under dilution was observed in all species.
Even though measurements of feline SAA signiﬁcantly deviated
from a linear model determined by runs test, slopes and Y-inter-
cepts did not differ signiﬁcantly from 1 and 0, respectively, in
any of the three species (Table 2). Therefore, the accuracy of the as-
say seems to be sufﬁcient for clinical diagnostic purposes.
Wider ranges of concentrations of feline and equine SAA was
measured in the present study (0–1113 mg/L and 0–>2500 mg/L,
respectively) compared to similar measurements in other studies
where feline SAA ranged from 0 to 153.5 mg/L (Kajikawa et al.,
1999; Sasaki et al., 2003; Hansen et al., 2006; Tamamoto
et al., 2008, 2009) and equine SAA from 0 to 800 mg/L (Hultèn
et al., 1999; Hultén and Demmers, 2002; Jacobsen et al., 2005,
2006b; Jacobsen and Andersen, 2007). Measurements of feline
and equine SAA using the novel LAT systematically exceeded SAA
measurements of the same samples when compared to a previ-
ously validated automated method used as reference method.
The difference can most likely be explained by differences in the
afﬁnity of the antibodies used in the assays: the monoclonal anti-
bodies in the novel LAT were selected to optimise cross-reactivity
to companion animal SAA, whereas the antibodies of the previ-
ously validated assay were optimised for human use only. As both
336 M. Christensen et al. / The Veterinary Journal 194 (2012) 332–337assays are calibrated with recombinant human SAA (thus measur-
ing human SAA equivalents), a higher afﬁnity to a speciﬁc SAA (e.g.
feline SAA) will translate into a higher SAA concentration read from
the calibration curve. If made available, the use of species speciﬁc
calibration material would compensate for this. The disagreement
should, however, not result in any problems of clinical signiﬁcance,
as long as the clinical decision levels for the novel LAT are adjusted
for the increased afﬁnity. The high degree of correlation between
the two methods for measuring SAA ensures a high degree of
agreement on clinical classiﬁcation between the novel LAT and
the previously validated method.
The overlap performance of SAA as a diagnostic marker of the
acute phase response in cats and horses has been well docu-
mented, showing high concentrations of SAA in diseased animals
with systemic inﬂammation and low SAA concentrations in ani-
mals with disorders without systemic inﬂammation or healthy
(Hultèn et al., 1999; Kajikawa et al., 1999; Sasaki et al., 2003; Jac-
obsen and Andersen, 2007; Tamamoto et al., 2008). In the present
study, the overlap performance of canine SAA measured by the LAT
was analysed in order to investigate whether comparable patterns
of concentrations were observed. SAA was measured in three
groups of dogs, with a comparable spectrum of ages and breeds.
Based on SAA measurements, dogs with marked acute phase re-
sponses could be distinguished from healthy dogs and diseased
dogs without systemic inﬂammation as in other species (Jacobsen
and Andersen, 2007; Tamamoto et al., 2008) and with other posi-
tive APPs (Kjelgaard-Hansen et al., 2003; Nakamura et al., 2008;
Yuki et al., 2010).
This novel LAT can seemingly be used for diagnostic purposes in
the assessment of the acute phase response in dogs by measuring
SAA concentrations between 0 and >3000 mg/L. In most cases, a
more narrow spectrum of SAA concentrations are measured in
dogs (Dabrowski et al., 2009; Martinez-Subiela et al., 2011), but
concentrations >3000 mg/L are occasionally observed (Lowrie
et al., 2009), making the working range of the assay relevant for
routine use in a general clinical setting.Conclusions
The LAT assay measures SAA in canine, feline, and equine serum
with analytical and overlap performance acceptable for clinical
purposes. The method is automated, rapid, and applicable for ran-
dom-access analysers facilitating routine use in diagnostic labora-
tories. Furthermore, since the LAT is based on monoclonal
antibodies, it may be associated with a strong long-term and in-
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